Ki Chung to Maximum Tolerated Dose
This is a "connection" page, showing publications Ki Chung has written about Maximum Tolerated Dose.
Connection Strength
0.139
-
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology. 2011; 81(2):65-72.
Score: 0.093
-
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021 10 01; 27(19):5236-5247.
Score: 0.047